These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24789302)

  • 1. Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors.
    Bachstetter AD; Watterson DM; Van Eldik LJ
    J Neuroimmune Pharmacol; 2014 Sep; 9(4):454-60. PubMed ID: 24789302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ).
    Bachstetter AD; Xing B; de Almeida L; Dimayuga ER; Watterson DM; Van Eldik LJ
    J Neuroinflammation; 2011 Jul; 8():79. PubMed ID: 21733175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
    Munoz L; Ralay Ranaivo H; Roy SM; Hu W; Craft JM; McNamara LK; Chico LW; Van Eldik LJ; Watterson DM
    J Neuroinflammation; 2007 Sep; 4():21. PubMed ID: 17784957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.
    Maphis N; Jiang S; Xu G; Kokiko-Cochran ON; Roy SM; Van Eldik LJ; Watterson DM; Lamb BT; Bhaskar K
    Alzheimers Res Ther; 2016 Dec; 8(1):54. PubMed ID: 27974048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo.
    Tate CM; Blosser W; Wyss L; Evans G; Xue Q; Pan Y; Stancato L
    J Biol Chem; 2013 Mar; 288(9):6743-53. PubMed ID: 23335506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The p38alpha mitogen-activated protein kinase limits the CNS proinflammatory cytokine response to systemic lipopolysaccharide, potentially through an IL-10 dependent mechanism.
    Bachstetter AD; Xing B; Van Eldik LJ
    J Neuroinflammation; 2014 Oct; 11():175. PubMed ID: 25297465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages.
    Smith SJ; Fenwick PS; Nicholson AG; Kirschenbaum F; Finney-Hayward TK; Higgins LS; Giembycz MA; Barnes PJ; Donnelly LE
    Br J Pharmacol; 2006 Oct; 149(4):393-404. PubMed ID: 16953188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction.
    Watterson DM; Grum-Tokars VL; Roy SM; Schavocky JP; Bradaric BD; Bachstetter AD; Xing B; Dimayuga E; Saeed F; Zhang H; Staniszewski A; Pelletier JC; Minasov G; Anderson WF; Arancio O; Van Eldik LJ
    PLoS One; 2013; 8(6):e66226. PubMed ID: 23840427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase.
    Guo X; Gerl RE; Schrader JW
    J Biol Chem; 2003 Jun; 278(25):22237-42. PubMed ID: 12637577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficiency in p38β MAPK fails to inhibit cytokine production or protect neurons against inflammatory insult in in vitro and in vivo mouse models.
    Xing B; Bachstetter AD; Van Eldik LJ
    PLoS One; 2013; 8(2):e56852. PubMed ID: 23457629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease.
    Rutigliano G; Stazi M; Arancio O; Watterson DM; Origlia N
    Neurobiol Aging; 2018 Oct; 70():86-91. PubMed ID: 30007168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective requirement of p38alpha MAPK in cytokine-dependent, but not antigen receptor-dependent, Th1 responses.
    Berenson LS; Yang J; Sleckman BP; Murphy TL; Murphy KM
    J Immunol; 2006 Apr; 176(8):4616-21. PubMed ID: 16585552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays.
    Ross S; Chen T; Yu V; Tudor Y; Zhang D; Liu L; Tamayo N; Dominguez C; Powers D
    Assay Drug Dev Technol; 2006 Aug; 4(4):397-409. PubMed ID: 16945013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2.
    Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5979-83. PubMed ID: 22901390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes.
    Zhou Z; Bachstetter AD; Späni CB; Roy SM; Watterson DM; Van Eldik LJ
    J Neuroinflammation; 2017 Apr; 14(1):75. PubMed ID: 28381303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease.
    Docena G; Rovedatti L; Kruidenier L; Fanning A; Leakey NA; Knowles CH; Lee K; Shanahan F; Nally K; McLean PG; Di Sabatino A; MacDonald TT
    Clin Exp Immunol; 2010 Oct; 162(1):108-15. PubMed ID: 20731675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level.
    Alam JJ; Krakovsky M; Germann U; Levy A
    PLoS One; 2020; 15(12):e0233073. PubMed ID: 33275615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of triazolopyridazinones as potent p38α inhibitors.
    Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.
    Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H
    Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
    Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
    Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.